Kintor Pharmaceutical Limited (HKG:9939)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.660
-0.030 (-1.78%)
Jun 17, 2025, 11:58 AM HKT
39.50%
Market Cap 733.80M
Revenue (ttm) 5.32M
Net Income (ttm) -165.26M
Shares Out 434.20M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,155,000
Average Volume 4,544,522
Open 1.740
Previous Close 1.690
Day's Range 1.630 - 1.740
52-Week Range 0.790 - 1.910
Beta -0.08
RSI 63.93
Earnings Date May 26, 2025

About Kintor Pharmaceutical

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 168
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9939
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.